上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2017, Vol. 37 ›› Issue (11): 1524-.doi: 10.3969/j.issn.1674-8115.2017.11.013

• 论著（临床研究） • 上一篇    下一篇

EGFR-TKI 对少见EGFR 21L861Q 突变的晚期非小细胞肺癌患者的治疗效果

胡章国，曹淑慧，钟华   

  1. 上海交通大学附属胸科医院呼吸内科，上海 200030
  • 出版日期:2017-11-28 发布日期:2018-01-10
  • 作者简介:胡章国（1989—），硕士生；电子信箱：chitmac@126.com
  • 基金资助:
    上海市教育委员会高峰高原学科建设计划（20161434）；上海市胸科医院院级课题（YZ2015-ZX12）

Efficacy of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR 21L861Q mutation#br#

HU Zhang-guo, CAO Shu-hui, ZHONG Hua   

  1. Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
  • Online:2017-11-28 Published:2018-01-10
  • Supported by:
     Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20161434; Foundation of Shanghai Chest Hospital, YZ2015-ZX12

PDF (PC)

1529

摘要： 目的 · 评价表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对少见 EGFR 基因 第 21 外显子 L861Q（21L861Q）突变的晚期 非小细胞肺癌（NSCLC）患者的治疗效果。方法 · 收集2011 年 6 月—2015 年 3 月在上海交通大学附属胸科医院接受EGFR-TKI 治疗 的 EGFR 21L861Q 突变的 21 例Ⅲ B 或Ⅳ期 NSCLC 患者的临床资料。对 TKI 治疗的客观缓解率（ORR）、疾病控制率（DCR）、无进展 生存期（PFS）和总生存期（OS）进行回顾性分析。结果 · 接受过TKI 治疗（一线+ 二线 + 三线）患者的ORR 和 DCR 分别为42.9% 和 66.7%；PFS 和 OS 分别为 7.03 个月（95% CI：5.50 ～ 8.69）和 22.80 个月（95%CI：16.22 ～ 25.65）。 结论 · EGFR-TKI 对少见 EGFR 21L861Q 突变的晚期 NSCLC 患者的治疗有效，但是效果不如常见突变。

关键词:  非小细胞肺癌, 表皮生长因子受体酪氨酸激酶抑制剂, EGFR 少见突变, 21L861Q

Abstract:

Objective · To evaluate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in non small cell lung cancer (NSCLC) patients with uncommon EGFR 21L861Q mutation.  Methods · Between June 2011 and Marth 2015, clinical data of 21 stage Ⅲ B/ Ⅳ NSCLC patients who received EGFR-TKI harboring uncommon 21L861Q mutation in EGFR at the Shanghai Chest Hospital were collected. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS ) and overall survival (OS ) of the patients under TKI therapy were retrospectively analyzed.  Results · ORR and DCR of the patients under TKIs therapy (first-line+second-line+third-line) were 42.9% and 66.7% respectively. PFS and OS of patients who received therapy that consisted of EGFR-TKIs (first-line+second-line+third-line) were 7.03 months (95% CI, 5.50-8.69) and 22.80 months (95% CI, 16.22-25.65).  Conclusion · Our post-hoc analyses demonstrated that EGFR-TKIs showed activity in patients with uncommon EGFR 21L861Q-mutant NSCLC, less effective than in those with common mutations.

Key words: non small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR uncommon mutations, 21L861Q

中图分类号: